Novo Is Highly Undervalued

Posted on by http://wealthcreation.club
Despite lowering their price target, UBS still projects “risk adjusted peak sales” of $75 billion annually until 2031 for Novo Nordisk. They believe CagriSema, despite disappointing trial results, could still show differentiation in type 2 diabetes treatment

To Profit From This News, Contact us today, and let us demonstrate how we can elevate your portfolio to new levels

Contact Us: bit.ly/Alpha-Binwani-Capital

Website: alphabinwanicapital.com

#NovoNordisk #CagriSema #Type2Diabetes #UBSAnalysis
Unknown's avatar

Published by http://wealthcreation.club

http://wealthcreation.club—We are educating regular people about how to be able to make more money in a disciplined way

Leave a comment